EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors
NCT07163325
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumor (Phase 1)
Interventions
DRUG:
EP102
Sponsor
Epics Therapeutics